[Federal Register: March 15, 1999 (Volume 64, Number 49)]
[Notices]               
[Page 12816]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15mr99-51]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to Girish C. 
Barua, Ph.D. at the Office of Technology Transfer, National Institutes 
of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 
20852-3804; telephone: 301/496-7057 ext. 263; fax: 301/402-0220; e-
mail: gb18tnih.gov. A signed Confidential Disclosure Agreement will be 
required to receive copies of the patent applications.

Mixing Arrangement and Method

Lesley Pesnicak (NIAID)
Serial No. 08/823,417 filed 25 Mar 97; U.S. Patent 5,810,773 issued 22 
Sep 98

    An arrangement for sterilely mixing two viscous fluids together. It 
consists of a base with removable stops to accommodate two syringes 
(different sizes can be used) and a 3-way stopcock. Two commercially 
available syringes are connected to a 3-way stopcock and fitted onto 
the base such that the flanges of the syringes are up against stops 
connected to the base and the 3 way stopcock is fitted into stops also 
connected to the base in such a manner that syringes and stopcock are 
unable to pull apart when the desired fluids are forced through the 
stopcock from one syringe to another. In this manner two fluids can be 
easily mixed without the loss for material which might result from the 
syringes popping off the stopcock and the ability to provide complete 
sterility. This device is especially good for emulsification of 
peptides.

Isolation of Amplified Genes Via cDNA Subtractive Hybridization

Bertrand C. Liang (NCI)
Serial No. 08/700, 763 filed 09 Aug 96; U.S. Patent 5,827,658 issued 27 
Oct 98

    A method of analyzing an amplified gene, including determining its 
copy number involves subtractive hybridization of cDNA libraries, one 
from the tissue of interest and the other containing biotinylated cDNA 
from normal tissue, where the annealed cDNA is removed by means of 
magnetic beads coated with streptevidin or avidin. The cDNA isolated 
after subtractive hybridization represents amplified DNA, and it is 
analyzed to determine what gene(s) were amplified. Furthermore, the 
copy number of the gene(s) can be estimated. The copy number thus 
determined can be correlated to the severity of a pathogenic state, to 
the prognosis or to treatment efficacy.

Method of Identifying and Using Drugs With Selective Effect Against 
Cancer Cells

George F. Vande Woude, Anne P. Monks, Han-Mo Koo (NCI) Serial No. 08/
260,515 filed 15 Jun 94; U.S. Patent 5,645,983 issued 08 Jul 97

    The invention covers a method of identifying drugs which 
selectively inhibit the growth of particular cancer cells. This is 
accomplished by contacting cancer cells, which differ as to the 
presence of a particular DNA sequence with a drug and measuring the 
effect of the drug on growth of the cells. A determination is then made 
as to whether there is a correlation between the growth rate and 
presence or absence of the DNA sequence.
    The invention may potentially be applied in research and 
development of cancer therapeutics, or as a diagnostic. It may provide 
the ability to design combinations of drugs for cancer treatment.

    Dated: March 5, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 99-6206 Filed 3-12-99; 8:45 am]
BILLING CODE 4140-01-M